Abrysvo Launch A Bright Spot For Pfizer In A Third Quarter Reset

 
• By Jessica Merrill

The RSV vaccine performed well in the third quarter but is in a competitive fight with GSK’s Arexvy. Pfizer also announced Phase III results for its mRNA-based flu vaccine.

bright spot
Pfizer's RSV vaccine got off to a strong start • Source: Shutterstock

More from Earnings

More from Business